The Genomics business benefited from 20% volume growth in oncology tests (legacy Tempus clinical testing) and higher average revenue per test, driven by increased Medicare reimbur ...

Tempus AI TEM, a Chicago-based company focused on precision medicine, is building network effects via its three ...

The U.S. Intravenous Immunoglobulin Market plays a crucial role in treating immunodeficiency diseases and various autoimmune disorders, reflecting a steady evolution influenced by advanced therapies ...

Ocular Therapeutix (OCUL) shares ended the last trading session 8.6% higher at $9.09. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session.

ADMA Biologics ADMA and Takeda TAK are leading players in the plasma derived immunoglobulin sector. ADMA markets ...

Takeda (TOKYO:4502/NYSE:TAK) today announced financial results for fiscal year 2024 (period ended March 31, 2025) with continued strong momentum in Growth & Launch Products offsetting loss of ...

“Takeda's success in delivering revenue and Core Operating Profit growth in FY2024 and our outlook for broadly flat revenue and profit in FY2025, demonstrates our ability to manage through one ...

OSAKA, Japan, May 08, 2025--Takeda (TOKYO:4502/NYSE:TAK) today announced financial results for fiscal year 2024 (period ended March 31, 2025) with continued strong momentum in Growth & Launch Products ...

JP Morgan sees strong growth for Ascentage Pharma, citing its late-stage cancer drugs. The biotech's 2024 sales surged 342% YoY, driven by a Takeda payment.

In this article, we discuss the 15 best fast growth stocks to buy right now. In the fourth quarter of 2024, the US Gross Domestic Product (GDP) expanded at an annual rate of 2.3%, slightly below ...